Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12458516 | 0.88 | TSHR (0.35) | TSHR | |
| SCHEMBL17886886 | 0.87 | CYP3A4 (0.43) | TSHR | |
| SCHEMBL17886946 | 0.87 | TSHR (0.45) | TSHR | |
| SCHEMBL10200642 | 0.83 | GRM5 (0.36) | TSHR | |
| SCHEMBL12312781 | 0.83 | HSD11B1 (0.33) | TSHR | |
| SCHEMBL13227074 | 0.83 | GRM5 (0.36) | TSHR | |
| SCHEMBL26247865 | 0.83 | GRM5 (0.36) | TSHR | |
| SCHEMBL15781124 | 0.83 | HSD11B1 (0.33) | TSHR | |
| SCHEMBL16624955 | 0.83 | CRHBP (0.33) | — | |
| SCHEMBL14768740 | 0.82 | CYP2D6 (0.44) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11679108-B2 | Aromatic heterocyclic compound, and pharmaceutical composition and use thereof | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| US-9493486-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHES INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | TSHR 2323/4885 |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | DAPK2, DAPK1, IDH3A | TSHR 2616/4885 |
| US-11679108-B2 | Aromatic heterocyclic compound, and pharmaceutical composition and use thereof | ENPP2, ADRM1, TPX2 | TSHR 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.